{"id":"tki","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Dermatologic reactions"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-15%","effect":"Hypertension"}]},"_chembl":{"chemblId":"CHEMBL522892","moleculeType":"Small molecule","molecularWeight":"392.44"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TKIs work by selectively inhibiting specific tyrosine kinases, which are enzymes involved in the activation of proteins that promote cell growth and survival. By blocking these enzymes, TKIs can prevent cancer cells from growing and dividing, ultimately leading to cell death.","oneSentence":"TKI inhibits tyrosine kinases to block cancer cell proliferation and survival.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:59.222Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic myeloid leukemia"},{"name":"Non-small cell lung cancer"},{"name":"Gastrointestinal stromal tumor"}]},"trialDetails":[{"nctId":"NCT07498595","phase":"EARLY_PHASE1","title":"TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2026-03-31","conditions":"EGFR-TKI-resistant Non-Small Cell Lung Cancer","enrollment":50},{"nctId":"NCT03793166","phase":"PHASE3","title":"Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-07","conditions":"Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes","enrollment":1175},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT07413757","phase":"","title":"CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-02","conditions":"Non-Small Cell Lung Cancer","enrollment":590},{"nctId":"NCT07493408","phase":"PHASE2","title":"Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-30","conditions":"Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia, Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL)","enrollment":45},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT05395741","phase":"PHASE1, PHASE2","title":"Regorafenib in Patients With Refractory Primary Bone Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Mother and Child, Warsaw, Poland","startDate":"2022-04-28","conditions":"Osteosarcoma, Ewing Sarcoma of Bone","enrollment":30},{"nctId":"NCT07491497","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC","status":"RECRUITING","sponsor":"TRIANA Biomedicines, Inc.","startDate":"2026-03-11","conditions":"ALK-positive NSCLC, ALK-Positive Lung Cancer, ALK-positive Non-small Cell Lung Cancer","enrollment":160},{"nctId":"NCT05805631","phase":"PHASE2","title":"Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC","status":"RECRUITING","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2024-08-01","conditions":"Carcinoma, Non-Small-Cell Lung, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis","enrollment":23},{"nctId":"NCT06765109","phase":"PHASE3","title":"Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC","status":"RECRUITING","sponsor":"Nuvalent Inc.","startDate":"2025-07-17","conditions":"Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive","enrollment":450},{"nctId":"NCT07185997","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations","status":"RECRUITING","sponsor":"ArriVent BioPharma, Inc.","startDate":"2025-12-17","conditions":"Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer","enrollment":480},{"nctId":"NCT06396065","phase":"PHASE3","title":"Phase III Study of AK112 for NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Summit Therapeutics","startDate":"2023-05-04","conditions":"Non-Squamous Non-small Cell Lung Cancer","enrollment":420},{"nctId":"NCT07489755","phase":"PHASE3","title":"TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen TargetRx Co., Ltd.","startDate":"2026-04-01","conditions":"Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia - Chronic Phase","enrollment":180},{"nctId":"NCT07489495","phase":"PHASE3","title":"A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-04-17","conditions":"Carcinoma, Renal Cell","enrollment":758},{"nctId":"NCT07354074","phase":"PHASE2","title":"Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-04","conditions":"Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive","enrollment":50},{"nctId":"NCT05143840","phase":"PHASE2","title":"Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase","status":"RECRUITING","sponsor":"Augusta University","startDate":"2022-04-22","conditions":"Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid","enrollment":100},{"nctId":"NCT07488572","phase":"PHASE2","title":"Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study","status":"ENROLLING_BY_INVITATION","sponsor":"Sun Yat-sen University","startDate":"2025-11-01","conditions":"Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell Carcinoma","enrollment":60},{"nctId":"NCT07049926","phase":"PHASE1, PHASE2","title":"Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-20","conditions":"Renal Cell Carcinoma","enrollment":140},{"nctId":"NCT07100080","phase":"PHASE2, PHASE3","title":"Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-11-05","conditions":"Non-Small Cell Lung Cancer","enrollment":596},{"nctId":"NCT06671379","phase":"PHASE3","title":"A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-11-29","conditions":"Non-small Cell Lung Cancer","enrollment":498},{"nctId":"NCT07479485","phase":"PHASE1, PHASE2","title":"MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)","status":"NOT_YET_RECRUITING","sponsor":"Lepu Biopharma Co., Ltd.","startDate":"2026-04","conditions":"Hepatocellular Carcinoma","enrollment":160},{"nctId":"NCT04077463","phase":"PHASE1","title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":701},{"nctId":"NCT07001995","phase":"PHASE2","title":"Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression","status":"NOT_YET_RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2026-05-01","conditions":"Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer NSCLC","enrollment":30},{"nctId":"NCT07235085","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy","status":"RECRUITING","sponsor":"Ocular Therapeutix, Inc.","startDate":"2025-11-17","conditions":"Non-Proliferative Diabetic Retinopathy","enrollment":930},{"nctId":"NCT07449936","phase":"PHASE3","title":"COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME","status":"RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2026-02-26","conditions":"Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)","enrollment":240},{"nctId":"NCT01248429","phase":"","title":"Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2010-11","conditions":"Cancer, Solid Tumor","enrollment":154},{"nctId":"NCT07230691","phase":"","title":"A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-12-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":380},{"nctId":"NCT05364073","phase":"PHASE1","title":"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"ArriVent BioPharma, Inc.","startDate":"2022-06-30","conditions":"Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer","enrollment":160},{"nctId":"NCT06716138","phase":"PHASE1","title":"A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Avistone Biotechnology Co., Ltd.","startDate":"2025-03-06","conditions":"Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration","enrollment":96},{"nctId":"NCT07467590","phase":"PHASE2","title":"Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-04-01","conditions":"Refractory Colorectal Cancer, Radiotherapy-Induced Immune Priming, Immune Response","enrollment":33},{"nctId":"NCT07463248","phase":"PHASE2","title":"PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Wang Xin","startDate":"2026-03-05","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":64},{"nctId":"NCT07155187","phase":"PHASE2, PHASE3","title":"A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-12-10","conditions":"Non-Small Cell Lung Cancer","enrollment":430},{"nctId":"NCT06282991","phase":"","title":"A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-07-22","conditions":"Non-Small Cell Lung Carcinoma","enrollment":73},{"nctId":"NCT04971226","phase":"PHASE3","title":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-06","conditions":"Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive","enrollment":406},{"nctId":"NCT07461727","phase":"PHASE1","title":"An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-10","conditions":"Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Liver Metastases","enrollment":15},{"nctId":"NCT05636267","phase":"PHASE1, PHASE2","title":"Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients","status":"TERMINATED","sponsor":"Akeso","startDate":"2023-02-10","conditions":"NSCLC","enrollment":59},{"nctId":"NCT07454850","phase":"","title":"A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-03-17","conditions":"Leukemia, Myeloid, Chronic-Phase","enrollment":400},{"nctId":"NCT05306301","phase":"PHASE2","title":"Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2022-10-05","conditions":"Chemotherapy, Leukemia, Acute Lymphoblastic","enrollment":32},{"nctId":"NCT07454226","phase":"NA","title":"ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Ph-Like, Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT06860386","phase":"PHASE2","title":"Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC","status":"SUSPENDED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2025-02-25","conditions":"Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma","enrollment":75},{"nctId":"NCT07449923","phase":"PHASE3","title":"CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME","status":"RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2026-02-09","conditions":"Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)","enrollment":240},{"nctId":"NCT06813664","phase":"PHASE2","title":"ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI)","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2026-04-01","conditions":"Metastatic NSCLC - Non-Small Cell Lung Cancer, OligoProgressive Metastatic Disease","enrollment":60},{"nctId":"NCT07449065","phase":"","title":"CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-06-01","conditions":"Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Microvascular Invasion (MVI)","enrollment":324},{"nctId":"NCT06668064","phase":"PHASE3","title":"A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56","status":"ACTIVE_NOT_RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2024-10-22","conditions":"Wet Age Related Macular Degeneration, wAMD","enrollment":400},{"nctId":"NCT06683742","phase":"PHASE3","title":"A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56","status":"ACTIVE_NOT_RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2024-11-27","conditions":"Wet Age Related Macular Degeneration, wAMD","enrollment":400},{"nctId":"NCT06481228","phase":"NA","title":"Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-06-04","conditions":"Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult","enrollment":82},{"nctId":"NCT04318938","phase":"PHASE2","title":"Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2020-03-30","conditions":"NSCLC","enrollment":118},{"nctId":"NCT02716116","phase":"PHASE1, PHASE2","title":"A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2016-06-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":334},{"nctId":"NCT07433400","phase":"","title":"Long-term Progression of Patients Treated and Monitored for Relapsed or Refractory Ph+ ALL","status":"RECRUITING","sponsor":"Group for Research in Adult Acute Lymphoblastic Leukemia","startDate":"2025-08-29","conditions":"Ph Positive ALL","enrollment":500},{"nctId":"NCT06830694","phase":"PHASE2","title":"Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment","status":"RECRUITING","sponsor":"Se-Hoon Lee","startDate":"2025-05-13","conditions":"Small Cell Carcinoma of Lung","enrollment":50},{"nctId":"NCT06043817","phase":"PHASE1, PHASE2","title":"First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations","status":"RECRUITING","sponsor":"Pierre Fabre Medicament","startDate":"2023-09-26","conditions":"Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation","enrollment":251},{"nctId":"NCT03042221","phase":"","title":"Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2016-05-10","conditions":"Non-Small Cell Carcinoma of Lung, TNM Stage 4, Non-Small Cell Lung Cancer, EGFR Gene Mutation","enrollment":100},{"nctId":"NCT04868877","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merus B.V.","startDate":"2021-04-28","conditions":"Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma","enrollment":194},{"nctId":"NCT05000294","phase":"PHASE1, PHASE2","title":"Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types","status":"SUSPENDED","sponsor":"University of Florida","startDate":"2021-12-07","conditions":"Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer","enrollment":29},{"nctId":"NCT06741085","phase":"PHASE2","title":"A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-12-13","conditions":"Non Small Cell Lung Cancer Metastatic","enrollment":56},{"nctId":"NCT07416058","phase":"PHASE2","title":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2026-01-31","conditions":"Lung Adenocarcinoma","enrollment":61},{"nctId":"NCT07414927","phase":"PHASE1, PHASE2","title":"A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Best-Link Bioscience, LLC","startDate":"2026-03-27","conditions":"Small Cell Carcinoma of Lung","enrollment":48},{"nctId":"NCT07415005","phase":"PHASE2","title":"Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-08-31","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT04557969","phase":"","title":"Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-18","conditions":"Gastric Cancer, Gastric Neoplasm, Gastrointestinal Stromal Sarcoma","enrollment":400},{"nctId":"NCT07410715","phase":"","title":"Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma (SWITCH)","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-03-01","conditions":"HCC - Hepatocellular Carcinoma, Watch & Wait, Surgery","enrollment":100},{"nctId":"NCT05498428","phase":"PHASE2","title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-11-11","conditions":"Carcinoma, Non-small-Cell Lung","enrollment":520},{"nctId":"NCT06991920","phase":"NA","title":"Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-06-30","conditions":"Adult ALL, MPAL","enrollment":50},{"nctId":"NCT05381753","phase":"","title":"Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World","status":"COMPLETED","sponsor":"CStone Pharmaceuticals","startDate":"2022-08-29","conditions":"Gastrointestinal Stromal Tumors","enrollment":61},{"nctId":"NCT07398599","phase":"NA","title":"Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2026-02-15","conditions":"Leptomeningeal Metastasis, Lung Neoplasms, Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT06706076","phase":"PHASE1, PHASE2","title":"A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations","status":"RECRUITING","sponsor":"BlossomHill Therapeutics","startDate":"2025-01-09","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":266},{"nctId":"NCT03133546","phase":"PHASE2","title":"Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2017-05-31","conditions":"Non Small Cell Lung Cancer Metastatic","enrollment":155},{"nctId":"NCT02891603","phase":"PHASE1, PHASE2","title":"A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-06-08","conditions":"Graft Vs Host Disease, GVHD","enrollment":40},{"nctId":"NCT05456191","phase":"PHASE3","title":"A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-11-21","conditions":"Philadelphia Chromosome-Positive Chronic Myeloid Leukemia","enrollment":568},{"nctId":"NCT07229339","phase":"PHASE2","title":"Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2027-06-01","conditions":"Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":16},{"nctId":"NCT06007937","phase":"PHASE1, PHASE2","title":"A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-08-17","conditions":"Non Small Cell Lung Cancer, Metastatic, Recurrent","enrollment":56},{"nctId":"NCT04184921","phase":"PHASE2","title":"Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients","status":"COMPLETED","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2019-01-01","conditions":"Lung Cancer Non-small Cell Stage IV","enrollment":216},{"nctId":"NCT07374120","phase":"","title":"Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-01","conditions":"Leukemia, Myeloid, Chronic-Phase","enrollment":1480},{"nctId":"NCT04626635","phase":"PHASE1, PHASE2","title":"A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-12-21","conditions":"Advanced Solid Tumors","enrollment":933},{"nctId":"NCT02853331","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-09-16","conditions":"Renal Cell Carcinoma","enrollment":861},{"nctId":"NCT02143466","phase":"PHASE1","title":"AZD9291 in Combination With Ascending Doses of Novel Therapeutics","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-08-05","conditions":"Advanced Non Small Cell Lung Cancer","enrollment":344},{"nctId":"NCT03610971","phase":"PHASE2","title":"Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-11-19","conditions":"Chronic Phase Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase","enrollment":24},{"nctId":"NCT07371910","phase":"PHASE3","title":"Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-06-12","conditions":"Metastatic Breast Cancer, HRD-Positive/HER2-Negative Advanced Breast Cancer","enrollment":200},{"nctId":"NCT05816252","phase":"PHASE2","title":"A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Klus Pharma Inc.","startDate":"2023-04-19","conditions":"Non-small Cell Lung Cancer","enrollment":356},{"nctId":"NCT07340398","phase":"PHASE2","title":"Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-12-25","conditions":"HER2-positive Early Breast Cancer","enrollment":200},{"nctId":"NCT05601973","phase":"PHASE2","title":"Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI","status":"ACTIVE_NOT_RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2023-03-27","conditions":"Non Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT07328009","phase":"PHASE2","title":"A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-25","conditions":"Hepato Cellular Carcinoma (HCC)","enrollment":350},{"nctId":"NCT04486833","phase":"PHASE1, PHASE2","title":"Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib","status":"RECRUITING","sponsor":"Genprex, Inc.","startDate":"2021-09-03","conditions":"Carcinoma, Non-Small Cell Lung","enrollment":158},{"nctId":"NCT02609776","phase":"PHASE1","title":"Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2016-05-24","conditions":"Non-Small-Cell Lung Cancer","enrollment":751},{"nctId":"NCT07343479","phase":"PHASE2","title":"Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2026-05-01","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Gene Mutations, Brain Metastasis","enrollment":45},{"nctId":"NCT05845671","phase":"PHASE1, PHASE2","title":"Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-07-17","conditions":"Lung Cancer, Non Small Cell Lung Cancer","enrollment":12},{"nctId":"NCT05089916","phase":"PHASE2","title":"Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"AIO-Studien-gGmbH","startDate":"2022-01-20","conditions":"NSCLC, EGFR Positive Non-small Cell Lung Cancer, Oligoprogression","enrollment":42},{"nctId":"NCT07338396","phase":"","title":"A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2026-01","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":3000},{"nctId":"NCT02296125","phase":"PHASE3","title":"AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12-03","conditions":"Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer","enrollment":674},{"nctId":"NCT07324876","phase":"","title":"A Multicenter Real-World Study on TKI Therapy After Progression on First-Line TKI/IO Therapy or TKI/IO Therapy After Progression on First-Line TKI in Chinese Patients With Metastatic Renal Cell Carcinoma (mRCC)","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-31","conditions":"RCC","enrollment":860},{"nctId":"NCT04872985","phase":"PHASE2","title":"Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-20","conditions":"Breast Cancer, Hormone-receptor Positive Breast Cancer","enrollment":140},{"nctId":"NCT03874858","phase":"PHASE2","title":"A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-03-22","conditions":"Chronic Myeloid Leukemia","enrollment":124},{"nctId":"NCT07310589","phase":"NA","title":"Effects of a Visual Interactive LINE Chatbot on Self-Management of EGFR-TKI Related Side Effects in Patients With Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2026-01-01","conditions":"Non-Small Cell Lung Cancer","enrollment":178},{"nctId":"NCT02511106","phase":"PHASE3","title":"AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2015-10-21","conditions":"Stage IB-IIIA Non-small Cell Lung Carcinoma","enrollment":682},{"nctId":"NCT06026410","phase":"PHASE1","title":"KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2023-10-18","conditions":"Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)","enrollment":300},{"nctId":"NCT05463224","phase":"PHASE2","title":"Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Se-Hoon Lee","startDate":"2023-01-02","conditions":"NSCLC","enrollment":150},{"nctId":"NCT07301424","phase":"PHASE2","title":"Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL","status":"NOT_YET_RECRUITING","sponsor":"University of Alberta","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia","enrollment":80},{"nctId":"NCT04777994","phase":"PHASE1","title":"Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors","status":"RECRUITING","sponsor":"Calico Life Sciences LLC","startDate":"2021-03-09","conditions":"Advanced Solid Tumor Cancer","enrollment":248},{"nctId":"NCT03817398","phase":"PHASE2","title":"Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-11-08","conditions":"Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","enrollment":110},{"nctId":"NCT04626024","phase":"PHASE2","title":"Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2020-12-22","conditions":"Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission","enrollment":100},{"nctId":"NCT01639508","phase":"PHASE2","title":"Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-07","conditions":"Non-Small Cell Lung Cancer","enrollment":86}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"ALOPECIA"},{"count":2,"reaction":"BLOOD POTASSIUM INCREASED"},{"count":2,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":2,"reaction":"PRURITUS"},{"count":1,"reaction":"IMMUNE-MEDIATED HEPATITIS"},{"count":1,"reaction":"INCORRECT PRODUCT ADMINISTRATION DURATION"},{"count":1,"reaction":"INSOMNIA"},{"count":1,"reaction":"PRODUCT USE ISSUE"},{"count":1,"reaction":"RASH"},{"count":1,"reaction":"TOOTH RESTORATION"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cohort 5 (ACC-TKI)","erlotinib","afatinib","gefitinib","Gefitinib/Erlotinib/Icotinib"],"phase":"phase_3","status":"active","brandName":"TKI","genericName":"TKI","companyName":"Shenzhen TargetRx Co., Ltd.","companyId":"shenzhen-targetrx-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TKI inhibits tyrosine kinases to block cancer cell proliferation and survival. Used for Chronic myeloid leukemia, Non-small cell lung cancer, Gastrointestinal stromal tumor.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}